FBRX

Forte Biosciences Inc

• TipRanks·2d ago

  Forte Biosciences’ FB102 Trial Moves Forward: What Investors Should Watch

• Seeking Alpha·08/14 09:00

  Alger Small Cap Growth Fund Q2 2026 Portfolio Review

• TipRanks·08/14 06:01

  Execution Risks Threaten Forte Biosciences–argenx Merger and Shareholder Value

• TipRanks·08/13 07:20

  Analysts’ Opinions Are Mixed on These Healthcare Stocks: Forte Biosciences (FBRX) and Demant (OtherWILLF)

• Seeking Alpha·08/06 12:13

  Alger Small Cap Focus Fund Q2 2026 Portfolio Review

• Benzinga·08/06 11:59

  argenx Commences $77/Shr Cash Tender Offer Through Subsidiary Avena Merger Sub To Acquire All Outstanding Shares Of Forte Biosciences

• Seeking Alpha·08/02 13:15

  Key deals this week: Ambarella, MarketAxess, argenx SE, TransDigm, and more

• NASDAQ·07/31 14:51

  Weekly Buzz:CIPLA, VTRS Win FDA Nod; BSX Cuts Jobs; ARGX Snaps Up FBRX; JNJ, GSK Strike Deals

• TipRanks·07/28 12:01

  First Tracks Biotherapeutics price target raised to $60 from $30 at Wedbush

• TipRanks·07/28 12:00

  Argenx price target raised to $1,050 from $1,000 at Wedbush

• Dow Jones·07/28 11:02

  Forte Biosciences Cut to Equal-Weight From Overweight by Barclays

• Dow Jones·07/28 11:02

  Forte Biosciences Price Target Raised to $77.00/Share From $74.00 by Barclays

• Benzinga·07/28 10:52

  Barclays Downgrades Forte Biosciences to Equal-Weight, Raises Price Target to $77

• TipRanks·07/28 10:15

  First Tracks Biotherapeutics price target raised to $55 from $30 at Wells Fargo

• TipRanks·07/28 08:45

  Forte Biosciences downgraded to Equal Weight from Overweight at Barclays